Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers
Articolo
Data di Pubblicazione:
2017
Citazione:
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers / T. Fujii, A. Barzi, A. Sartore-Bianchi, A. Cassingena, G. Siravegna, D.D. Karp, S.A. Piha-Paul, V. Subbiah, A.M. Tsimberidou, H.J. Huang, S. Veronese, F. Di Nicolantonio, S. Pingle, C.R.T. Vibat, S. Hancock, D. Berz, V.O. Melnikova, M.G. Erlander, R. Luthra, E.S. Kopetz, F. Meric-Bernstam, S. Siena, H.J. Lenz, A. Bardelli, F. Janku. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 23:14(2017 Jul), pp. 3657-3666.
Abstract:
Purpose: Tumor-derived cell-free DNA (cfDNA) from urine of patients with cancer offers noninvasive biological material for detection of cancer-related molecular abnormalities such as mutations in Exon 2 of KRASExperimental Design: A quantitative, mutation-enrichment next-generation sequencing test for detecting KRASG12/G13 mutations in urine cfDNA was developed, and results were compared with clinical testing of archival tumor tissue and plasma cfDNA from patients with advanced cancer.Results: With 90 to 110 mL of urine, the KRASG12/G13 cfDNA test had an analytical sensitivity of 0.002% to 0.006% mutant copies in wild-type background. In 71 patients, the concordance between urine cfDNA and tumor was 73% (sensitivity, 63%; specificity, 96%) for all patients and 89% (sensitivity, 80%; specificity, 100%) for patients with urine samples of 90 to 110 mL. Patients had significantly fewer KRASG12/G13 copies in urine cfDNA during systemic therapy than at baseline or disease progression (P = 0.002). Compared with no changes or increases in urine cfDNA KRASG12/G13 copies during therapy, decreases in these measures were associated with longer median time to treatment failure (P = 0.03).Conclusions: A quantitative, mutation-enrichment next-generation sequencing test for detecting KRASG12/G13 mutations in urine cfDNA had good concordance with testing of archival tumor tissue. Changes in mutated urine cfDNA were associated with time to treatment failure.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
T. Fujii, A. Barzi, A. Sartore-Bianchi, A. Cassingena, G. Siravegna, D.D. Karp, S.A. Piha-Paul, V. Subbiah, A.M. Tsimberidou, H.J. Huang, S. Veronese, F. Di Nicolantonio, S. Pingle, C.R.T. Vibat, S. Hancock, D. Berz, V.O. Melnikova, M.G. Erlander, R. Luthra, E.S. Kopetz, F. Meric-Bernstam, S. Siena, H.J. Lenz, A. Bardelli, F. Janku
Link alla scheda completa: